Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

Abstract Background In Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9®) received the European market authorization in 2015 to protect, with only 2 doses, against around 90% of all H...

Full description

Bibliographic Details
Main Authors: Francesco Saverio Mennini, Paolo Bonanni, Florence Bianic, Chiara de Waure, Gianluca Baio, Giacomo Plazzotta, Mathieu Uhart, Alessandro Rinaldi, Nathalie Largeron
Format: Article
Language:English
Published: BMC 2017-07-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Cost-effectiveness
Italy
HPV
Cervical cancer
Vaccination
Online Access:http://link.springer.com/article/10.1186/s12962-017-0073-8

Internet

http://link.springer.com/article/10.1186/s12962-017-0073-8

Similar Items